Medoc Ltd.

Nov 13, 2022

Mounting evidence for the value of QST use in Diabetes medicine

Updated: Dec 22, 2022

In commemoration of World Diabetes Day, we would like to shine a spotlight on the many studies which have been performed over the years in the study of Diabetes and Diabetic Neuropathy using Medoc’s thermal and vibratory quantitative sensory testing (QST) equipment.

Apart from QST use in research on the effects of Diabetes on peripheral sensory nerve function, Medoc’s devices are in wide-spread clinical use for large and small fiber functionality assessment in diabetic patients in many countries around the world, among them: Korea, China, Taiwan, United Kingdom, Germany, Israel, Scandinavia and others.

Quantitative sensory testing is sensitive enough to detect pre-clinical sensory changes. This could be used to prevent further harm by a more meticulous patient follow-up, and patients’ adjustment of lifestyle.

Read our past blogs on this subject below.

Bariatric surgery´s effects on diabetic neuropathy

Cold perception threshold predicts serious renal complications in Type 2 Diabetes

Is polyneuropathy reversible?

Thermal quantitative sensory testing proves pre-clinically relevant in type 2 Diabetes

New technology may change the diagnosis and management of diabetic neuropathy

Relationship between decline in peripheral nerve function and glycemic control in Diabetes type 1